Buscar
Mostrando ítems 1-10 de 105
Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon
(Ferrata Storti FoundationPaviaItália, 1998)
Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2014-10-01)
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular ...
Identification of driver and subclonal mutations in ASXL1 and IDH1/IDH2 genes in an Argentine series of patients with myelofibrosis
(Wiley Blackwell Publishing, Inc, 2018-08)
Myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic stem cells, progressive bone marrow fibrosis, abnormal cytokine expression, anemia, ...
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
(Faculdade de Medicina / USP, 2013)
Treatment Of Rats With The Jak-2 Inhibitor Fedratinib Does Not Lead To Experimental Wernicke's Encephalopathy
(Elsevier Ireland LTDClare, 2017)
JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
(Sociedade Brasileira de Genética, 2007)
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2011-12-01)
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following ...